These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 29668748)

  • 81. Healthcare worker knowledge, attitudes, and beliefs regarding tuberculosis preventive therapy in rural South Africa: A content analysis using the consolidated framework for implementation research.
    van de Water B; Wilson M; le Roux K; Gaunt B; Gimbel S; Ware N
    Res Sq; 2023 May; ():. PubMed ID: 37292734
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Spatial heterogeneity of extensively drug resistant-tuberculosis in Western Cape Province, South Africa.
    Sy KTL; Leavitt SV; de Vos M; Dolby T; Bor J; Horsburgh CR; Warren RM; Streicher EM; Jenkins HE; Jacobson KR
    Sci Rep; 2022 Jun; 12(1):10844. PubMed ID: 35760977
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Association of HIV infection and antiretroviral therapy with the occurrence of an unfavorable TB treatment outcome in a rural district hospital in Eastern Cape, South Africa: A retrospective cohort study.
    van de Water BJ; Fulcher I; Cilliers S; Meyer N; Wilson M; Young C; Gaunt B; le Roux K
    PLoS One; 2022; 17(4):e0266082. PubMed ID: 35381042
    [TBL] [Abstract][Full Text] [Related]  

  • 84. A Systematic Review of Economic Evaluations of Active Tuberculosis Treatments.
    Byun JY; Kim HL; Lee EK; Kwon SH
    Front Pharmacol; 2021; 12():736986. PubMed ID: 34966276
    [No Abstract]   [Full Text] [Related]  

  • 85. Diverse clinical and social circumstances: developing patient-centred care for DR-TB patients in South Africa.
    Mitrani L; Dickson-Hall L; Le Roux S; Hill J; Loveday M; Grant AD; Kielmann K; Mlisana K; Moshabela M; Nicol MP; Black J; Cox H
    Public Health Action; 2021 Sep; 11(3):120-125. PubMed ID: 34567987
    [TBL] [Abstract][Full Text] [Related]  

  • 86. TB management in the European Union/European Economic Area: a multi-centre survey.
    Sotgiu G; Rosales-Klintz S; Centis R; D'Ambrosio L; Verduin R; Correia AM; Cirule A; Duarte R; Gadzheva B; Gualano G; Kunst H; Palmieri F; Riekstina V; Stefanova D; Tiberi S; van der Werf MJ; Migliori GB
    Int J Tuberc Lung Dis; 2021 Feb; 25(2):126-133. PubMed ID: 33656424
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Decentralized Care for Rifampin-Resistant Tuberculosis, Western Cape, South Africa.
    Leavitt SV; Jacobson KR; Ragan EJ; Bor J; Hughes J; Bouton TC; Dolby T; Warren RM; Jenkins HE
    Emerg Infect Dis; 2021; 27(3):728-739. PubMed ID: 33622466
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Treatment outcomes among tuberculosis patients in Jeddah, Saudi Arabia: Results of a community mobile outreach directly observed Treatment, Short-course (DOTS) project, compared to a standard facility-based DOTS: A randomized controlled trial.
    Al-Sahafi A; Al-Sayali MM; Mandoura N; Shah HBU; Al Sharif K; Almohammadi EL; Abdul-Rashid OA; Assiri M; Buksh MF; Alali MM; Al-Garni A; Al-Garni F; Al-Zahrani A; Khalawi A; Alawi M; Moawwad AL; Almalki AIA; Al-Osaimi MM
    J Clin Tuberc Other Mycobact Dis; 2021 Feb; 22():100210. PubMed ID: 33490640
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Preparing the healthcare workforce in South Africa for short-course rifampicin-resistant TB treatment: inter-professional training and task-sharing considerations.
    Farley JE; Ndjeka N; Mlandu K; Lowensen K; Geiger K; Nguyen Y; Budhathoki C; Stamper PD
    Hum Resour Health; 2021 Jan; 19(1):6. PubMed ID: 33407541
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
    Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
    PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Economic evaluation of short treatment for multidrug-resistant tuberculosis, Ethiopia and South Africa: the STREAM trial.
    Madan JJ; Rosu L; Tefera MG; van Rensburg C; Evans D; Langley I; Tomeny EM; Nunn A; Phillips PP; Rusen ID; Squire SB;
    Bull World Health Organ; 2020 May; 98(5):306-314. PubMed ID: 32514196
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Managing multidrug-resistant tuberculosis in South Africa: a budget impact analysis.
    Masuku SD; Berhanu R; Van Rensburg C; Ndjeka N; Rosen S; Long L; Evans D; Nichols BE
    Int J Tuberc Lung Dis; 2020 Apr; 24(4):376-382. PubMed ID: 32317060
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Surveillance to maintain the sensitivity of genotype-based antibiotic resistance diagnostics.
    Hicks AL; Kissler SM; Lipsitch M; Grad YH
    PLoS Biol; 2019 Nov; 17(11):e3000547. PubMed ID: 31714937
    [TBL] [Abstract][Full Text] [Related]  

  • 94. High non-compliance rate with anti-tuberculosis treatment: a need to shift facility-based directly observed therapy short course (DOTS) to community mobile outreach team supervision in Saudi Arabia.
    AlSahafi AJ; Shah HBU; AlSayali MM; Mandoura N; Assiri M; Almohammadi EL; Khalawi A; AlGarni A; Filemban MK; AlOtaibe AK; AlFaifi AWA; AlGarni F
    BMC Public Health; 2019 Aug; 19(1):1168. PubMed ID: 31455324
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Cost outcome analysis of decentralized care for drug-resistant tuberculosis in Johannesburg, South Africa.
    van Rensburg C; Berhanu R; Hirasen K; Evans D; Rosen S; Long L
    PLoS One; 2019; 14(6):e0217820. PubMed ID: 31170207
    [TBL] [Abstract][Full Text] [Related]  

  • 96. MDR-TB patients in KwaZulu-Natal, South Africa: Cost-effectiveness of 5 models of care.
    Loveday M; Wallengren K; Reddy T; Besada D; Brust JCM; Voce A; Desai H; Ngozo J; Radebe Z; Master I; Padayatchi N; Daviaud E
    PLoS One; 2018; 13(4):e0196003. PubMed ID: 29668748
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Community-based care vs. centralised hospitalisation for MDR-TB patients, KwaZulu-Natal, South Africa.
    Loveday M; Wallengren K; Brust J; Roberts J; Voce A; Margot B; Ngozo J; Master I; Cassell G; Padayatchi N
    Int J Tuberc Lung Dis; 2015 Feb; 19(2):163-71. PubMed ID: 25574914
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care.
    Brust JC; Shah NS; Scott M; Chaiyachati K; Lygizos M; van der Merwe TL; Bamber S; Radebe Z; Loveday M; Moll AP; Margot B; Lalloo UG; Friedland GH; Gandhi NR
    Int J Tuberc Lung Dis; 2012 Aug; 16(8):998-1004. PubMed ID: 22668560
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review.
    Laurence YV; Griffiths UK; Vassall A
    Pharmacoeconomics; 2015 Sep; 33(9):939-55. PubMed ID: 25939501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.